IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy
Open Access
- 5 April 2018
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (7)
Abstract
Tumor-induced expansion of Tregs is a significant obstacle to cancer immunotherapy. However, traditional approaches to deplete Tregs are often inefficient, provoking autoimmunity. We show here that administration of IL-27–expressing recombinant adeno-associated virus (AAV–IL-27) significantly inhibits tumor growth and enhances T cell responses in tumors. Strikingly, we found that AAV–IL-27 treatment causes rapid depletion of Tregs in peripheral blood, lymphoid organs, and — most pronouncedly — tumor microenvironment. AAV–IL-27–mediated Treg depletion is dependent on IL-27 receptor and Stat1 in Tregs and is a combined result of CD25 downregulation in Tregs and inhibition of IL-2 production by T cells. In combination with a GM-CSF vaccine, AAV–IL-27 treatment not only induced nearly complete tumor rejection, but also resulted in amplified neoantigen-specific T cell responses. AAV–IL-27 also dramatically increased the efficacy of anti–PD-1 therapy, presumably due to induction of PD-L1 in T cells and depletion of Tregs. Importantly, AAV–IL-27 therapy did not induce significant adverse events, partially due to its induction of IL-10. In a plasmacytoma mouse model, we found that IL-10 was required for AAV–IL-27–mediated tumor rejection. Thus, our study demonstrates the potential of AAV–IL-27 as an independent cancer therapeutic and as an efficient adjuvant for cancer immunotherapy.Keywords
Funding Information
- National Institutes of Health (CA198037)
- National Natural Science Foundation of China (81572805)
This publication has 55 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Interleukin-27 Priming of T Cells Controls IL-17 Production In trans via Induction of the Ligand PD-L1Immunity, 2012
- Advancements in adeno-associated viral gene therapy approaches: exploring a new horizonF1000 Medicine Reports, 2011
- A Role for IL-27 in Limiting T Regulatory Cell PopulationsThe Journal of Immunology, 2011
- IL-12 and IL-27 Sequential Gene Therapy via Intramuscular Electroporation Delivery for Eliminating Distal Aggressive TumorsThe Journal of Immunology, 2010
- Immunologic and Therapeutic Synergy of IL-27 and IL-2: Enhancement of T Cell Sensitization, Tumor-Specific CTL Reactivity and Complete Regression of Disseminated Neuroblastoma Metastases in the Liver and Bone MarrowThe Journal of Immunology, 2009
- B7 Blockade Alters the Balance between Regulatory T Cells and Tumor-reactive T Cells for Immunotherapy of CancerClinical Cancer Research, 2009
- Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5BGenes & Development, 2008
- IL‐27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1European Journal of Immunology, 2007
- Potent Antitumor Activity of Interleukin-27Cancer Research, 2004